Beam Therapeutics (NASDAQ:BEAM - Get Free Report) posted its earnings results on Tuesday. The company reported ($1.17) earnings per share for the quarter, missing the consensus estimate of ($1.16) by ($0.01), Briefing.com reports. Beam Therapeutics had a negative return on equity of 16.22% and a negative net margin of 40.56%. The company had revenue of $14.30 million during the quarter, compared to analyst estimates of $14.52 million. During the same quarter last year, the firm posted ($1.22) earnings per share. The firm's revenue for the quarter was down 16.9% compared to the same quarter last year.
Beam Therapeutics Trading Down 1.8 %
Shares of NASDAQ BEAM opened at $23.93 on Wednesday. Beam Therapeutics has a 1 year low of $18.85 and a 1 year high of $49.50. The firm's 50-day moving average is $24.23 and its 200-day moving average is $24.62. The firm has a market capitalization of $1.97 billion, a PE ratio of -13.22 and a beta of 1.86.
Analyst Ratings Changes
BEAM has been the topic of several recent analyst reports. Leerink Partners upgraded shares of Beam Therapeutics from a "market perform" rating to an "outperform" rating and lifted their target price for the stock from $27.00 to $39.00 in a report on Wednesday. JPMorgan Chase & Co. lifted their target price on Beam Therapeutics from $45.00 to $48.00 and gave the stock an "overweight" rating in a research report on Wednesday, August 7th. Barclays decreased their target price on shares of Beam Therapeutics from $33.00 to $31.00 and set an "equal weight" rating on the stock in a research report on Wednesday, August 7th. Scotiabank began coverage on Beam Therapeutics in a research note on Wednesday, October 16th. They issued a "sector outperform" rating and a $24.00 price target on the stock. Finally, Stifel Nicolaus raised their price objective on shares of Beam Therapeutics from $66.00 to $69.00 and gave the stock a "buy" rating in a report on Wednesday, September 11th. Four investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $45.18.
Read Our Latest Report on Beam Therapeutics
Insider Buying and Selling
In related news, CEO John M. Evans sold 60,000 shares of Beam Therapeutics stock in a transaction that occurred on Monday, September 30th. The shares were sold at an average price of $24.60, for a total transaction of $1,476,000.00. Following the transaction, the chief executive officer now owns 938,659 shares of the company's stock, valued at $23,091,011.40. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In other Beam Therapeutics news, CEO John M. Evans sold 60,000 shares of the business's stock in a transaction dated Monday, September 30th. The stock was sold at an average price of $24.60, for a total value of $1,476,000.00. Following the completion of the transaction, the chief executive officer now directly owns 938,659 shares of the company's stock, valued at approximately $23,091,011.40. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, President Giuseppe Ciaramella sold 51,110 shares of the firm's stock in a transaction dated Monday, October 14th. The stock was sold at an average price of $26.27, for a total value of $1,342,659.70. Following the sale, the president now directly owns 160,260 shares in the company, valued at approximately $4,210,030.20. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 111,784 shares of company stock valued at $2,834,485 over the last ninety days. Insiders own 4.20% of the company's stock.
Beam Therapeutics Company Profile
(
Get Free Report)
Beam Therapeutics Inc, a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a.
Featured Stories
Before you consider Beam Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Beam Therapeutics wasn't on the list.
While Beam Therapeutics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.